MARKET

RXRX

RXRX

Recursion Pharmaceuticals, Inc.
NASDAQ
4.200
-0.130
-3.00%
Pre Market: 4.200 -0.001 -0.01% 08:40 12/16 EST
OPEN
4.345
PREV CLOSE
4.330
HIGH
4.360
LOW
4.144
VOLUME
116.29K
TURNOVER
--
52 WEEK HIGH
12.36
52 WEEK LOW
3.790
MARKET CAP
2.18B
P/E (TTM)
-2.3213
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RXRX last week (1208-1212)?
Weekly Report · 1d ago
Platform Technologies Drive $211B Surge in Precision Cancer Treatment
Barchart · 5d ago
Recursion Pharmaceuticals: Artificial Intelligence, Real Disappointment
Seeking Alpha · 6d ago
Is Early REC-4881 Trial Success Reframing the AI-Drug Discovery Investment Case For Recursion (RXRX)?
Simply Wall St · 6d ago
Cautious Hold Rating on Recursion Pharmaceuticals Amid Promising REC-4881 Data and Safety Concerns
TipRanks · 12/09 10:27
Recursion Pharmaceuticals (RXRX): Revisiting Valuation After a Tentative Share Price Rebound
Simply Wall St · 12/08 23:34
Why Recursion Pharamaceuticals Topped the Market Today
The Motley Fool · 12/08 22:30
Recursion rises on new data for asset for polyps
Seeking Alpha · 12/08 18:46
More
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.

Webull offers Recursion Pharmaceuticals Inc stock information, including NASDAQ: RXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RXRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RXRX stock methods without spending real money on the virtual paper trading platform.